News Releases

December 2020

December 7, 2020 12/7/2020 Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders

December 4, 2020 12/4/2020 New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

December 1, 2020 12/1/2020 Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific

December 1, 2020 12/1/2020 World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19

November 2020

November 24, 2020 11/24/2020 Announcement of Making Nihon Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary Through Simple Share Exchange

November 13, 2020 11/13/2020 Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema

November 5, 2020 11/5/2020 Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting

October 2020

October 29, 2020 10/29/2020 Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

October 29, 2020 10/29/2020 Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)